Guerbet has decided to implement an ambitious plan to better capture growth opportunities and evolving trends in its markets.
In Diagnostic Imaging, the MR contrast media market, which is estimated to represent approx. €1.0bn, is expected to face slower growth perspectives in value with the threat of generic penetration and associated pricing pressure that may offset the growth in volume.
CT & Cath Lab Contrast Media
The CT & Cath Lab contrast media market, which is estimated to represent c. €2.7bn, is expected to grow sustainably at a low single-digit rate.
At the same time, Guerbet believes that there are significant growth opportunities in medical devices and services for diagnostic contrast media, a market with an estimated size of c. €1.2bn.
The Interventional Imaging underlying markets are underpinned by a strong drive toward minimally invasive surgical procedures, which require the use of contrast media. Guerbet believes that it can address targeted market segments with an estimated combined value in excess of c. €1.6bn, leveraging its products portfolio and expertise.
Such market segments, including interventional oncology, interventional radiology embolization and interventional radiology delivery, would represent significant growth opportunities for Guerbet.
The pillars - Internal Boost - External Boost - Growth Opportunity
Guerbet has decided to implement an ambitious strategic plan to better capture growth opportunities in a context of evolving trends in its markets.
The GEAR 2023 strategic plan is built around four pillars: